Comparison of lipid control therapy for hypercholesterolemic patients received aortic valve replacement

Comparison of lipid control therapy for hypercholesterolemic patients received aortic valve replacement - Lipid control therapy for aortic valve replacement

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000006887

Enrollment

Registered

2011-12-31

Start date

2012-01-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Hypercholestelomic patients with aortic valve replacement for aortic valve stemosis

Interventions

Conventional Therapy Group: Target LDL-C levels are more than 100mg/dL and in compliance with JASGL2007.Any hypolipidemic drugs are available. Aggressive Therapy Group: 5mg Rosuvastatin will be orally

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1 Patients with aortic stenosis who had aortic valve replacement with biological valves. 2. Patients who are able to submit written consent agreement by themselves 3. LDL-C>140mg/dL(LDL-C>100mg/dL for patients received lipied lowering therapy) 4. Patients without a history of coronary artery disease

Exclusion criteria

Exclusion criteria: 1. Patient with a history of coronary artery disease 2. Patients with a history of sensitivity to statins 3. Patients with active hepatic disease(ALT or AST>100IU/L or total bilirubin>2.5mg/dL) 4. Patient on hemodialysis 5. Patients with fasting serum TG >= 1000 mg/dL. 6. Patients with CK > 500 IU/L. 7. Patients that are pregnant or potentially pregnant, patients breast-feeding, or patients aiming to become pregnant during the clinical trial. 8. Patients with drug abuse or alcoholic 9. Patients who are ineligible in the opinion of the investigator

Design outcomes

Primary

Measure	Time frame
Prosthetic valve dysfunction	—

Countries

Japan

Contacts

Public ContactYoshihisa Morimoto

Awaji Hospital, Hyogo, Japan Division of Cardiovascular Surgery

yoshimor@gmail.com0799-24-5704

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026